Mechanisms of enhanced non-viral gene delivery to human mesenchymal stem cells induced by glucocorticoid priming

Conference Dates

June 5-9, 2018


Background: Because of unique roles in wound healing, trophic tissue support, immunomodulation, differentiation ability, and immune privileged status, human mesenchymal stem cells (hMSCs), which can be easily derived from many adult tissues (e.g. bone marrow (BMSCs) and adipose tissue (AMSCs)), are under intense study for the applications of cell and gene therapeutics, as well as tissue engineering and regenerative medicine1. Genetic modification of hMSCs could allow for targeted delivery of transgenic therapeutic factors or genetically-guided differentiation. Non-viral gene delivery (i.e. cationic polymer- and lipid-mediated) is safer and more flexible than immunogenic and mutagenic viral vectors2, but it is less effective, especially in hMSCs (i.e. maximum 10-30% transfection)3. As part of an approach to understand molecular mechanisms of non-viral gene delivery4 and ‘prime’ cells to be more receptive to transfection5, our lab recently demonstrated that transgene expression from lipofected hMSCs can be increased about 10-fold by priming cells, 30 mins before plasmid DNA (pDNA) transfection, with 100 nM dexamethasone (DEX), a glucocorticoid (Gc) drug, relative to EtOH vehicle control (VC)6. This work investigates the mechanisms by which Gc priming enhances non-viral gene delivery, which are currently unknown. Studies provide insights into the biological processes of Gc priming and transfection to inform future gene delivery technologies, and characterize a simple protocol to significantly enhance non-viral gene delivery of therapeutic transgenes for future clinical applications.

Please click Additional Files below to see the full abstract.

29.pdf (193 kB)

This document is currently not available here.